Viewpoint: Medicare should cover Aduhelm only for patients who participate in trials

The only way for Medicare to safely determine if Biogen's controversial Alzheimer's drug, Aduhelm, works is to cover the treatment only for patients who receive it in trials, two physicians wrote in an op-ed published Jan. 3 in Bloomberg. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive